Abstract. Since differential expression of microRNAs (miRNAs) has been found to be highly associated with several types of cancer, the goal of the present study was to identify an miRNA fingerprint as a non-invasive diagnostic tool to detect urinary bladder cancer using the easily accessible samples of whole blood and urine. Blood and urine samples from 4 controls and from patients suffering from superficial and invasive bladder cancer were analyzed using miRNA microarray consisting of 754 human miRNAs from the Sanger database v14. Using RT-qPCR technique, 6 of the differentially expressed miRNAs were validated in the controls (20 blood, 19 urine samples) and patients with superficial (18 blood, 16 urine samples) or invasive (20 blood and urine samples each) tumours. Three blood miRNAs (miR-26b-5p, miR-144-5p, miR-374-5p) were found to be significantly upregulated in invasive bladder tumour patients (P<0.05) when compared to the control group. The expression of 2 miRNAs (miR-618, miR-1255b-5p) in the urine of patients with invasive tumours was significantly (P<0.05) increased in comparison to the control group. Blood miR-26b-5p detected the presence of invasive bladder tumours with 94% specificity and 65% sensitivity. The urine miR-1255b-5p reached 68% specificity and 85% sensitivity in the diagnosis of invasive tumours. This pilot study represents the first characterization of an miRNA profile for urinary bladder tumours in whole blood samples. In addition, it was shown that invasive bladder tumours could be identified by differentially expressed urine miRNAs. Further studies are needed to test the clinical usefulness for bladder cancer detection and surveillance.
Introduction
Urinary bladder cancer (BC) is the fifth most common malignancy. In the US, every year approximately 15,000 individuals succumb to this disease (1) . The diagnostic 'gold standard' in cases of urinary BC is cystoscopy, an invasive and relatively expensive procedure. Non-invasive urine cytology shows diagnostic high specificity but has the disadvantage of low sensitivity. Numerous urine-based tests such as bladder tumour antigen (BTA), nuclear matrix protein 22 (NMP22) or FISH cannot replace cystoscopy or cytology for diagnosis and follow-up examination (2) . Thus, the development of non-invasive diagnostic markers for the detection of BC is an essential objective in urology.
Several studies have shown that microRNAs (miRNAs) are involved in various biological processes, including tumourigenesis (3, 4) . miRNAs act as oncogenes or tumour-suppressor genes depending on the target that they regulate. The detection of differentially expressed miRNAs in tissues and body fluids is becoming increasingly important. Specific miRNA profiles have been identified for several types of carcinomas, among them urinary BC. The results are partly contradictory since different array platforms, sample processing modes, patient groups, and normalization strategies were used (5) (6) (7) (8) (9) (10) (11) . miRNAs in easily accessible body fluids could reflect tissue situation and are therefore of great, diagnostic and prognostic interest. Data regarding the detection of miRNAs in urine samples have been rarely published (12) (13) (14) (15) (16) . In bladder cancer, urinary miR-126 was described as a specific indicator of BC (16) , while overexpressed miR-96 and miR-183 were found to be correlated to tumour stage and grade (15) . Another study showed a characteristic panel of 3 miRNAs (miR-15b/ miR-135b/miR-1224-3p) in urine sediments for detecting urothelial cell carcinomas (12) .
We analyzed the miRNA expression profile in whole blood and urine samples from patients with superficial and invasive bladder tumours in comparison with healthy individuals. In a first step, an miRNA microarray technology identified a panel of significant miRNAs. In a second step, following investigation of a greater number of patients, the expression level of a limited number of selected differentially expressed miRNAs was validated using real-time quantitative PCR (RT-qPCR).
In blood samples, 3 miRNAs (miR-26b-5p, miR-144-5p, miR-374b-5p) were identified as discriminators between invasive tumours and the control group, while 3 other miRNAs (miR-520e, miR-618, miR-1255b-5p) were significantly increased in urine samples of patients with invasive tumours.
Materials and methods
Blood and urine of patient groups and controls. Blood and urine samples were collected from BC patients without metastasis and from a control group including healthy individuals and patients with benign urological diseases. All samples were collected immediately before transurethral resection of BC or cystectomy at the Charité University Hospital between 2010 and 2012. Following surgery, tumour classification was established according to the UICC 2010 TNM system. The study was approved by the Human Use Committee of our hospital (file: EA1/187/09), and informed consent of all patients was obtained. All BCs were transitional cell carcinomas; samples from patients with CIS were not investigated. Blood samples were collected and stored using PAXgene™ blood RNA tubes (Becton-Dickinson, Heidelberg, Germany). Urine collection (30 ml) was performed with a urine RNA concentration, preservation and isolation kit (Norgen Biotek Corp., Thorold, Canada). The study was performed on two independent sample sets of blood and urine. Set one included 12 blood and urine (Table I) and set two, 58 blood and 55 urine samples (Table II) , respectively. The demographic and clinicopathological characteristics of the study groups are summarized in Tables I and II . Samples from set one were used for miRNA profiling on a microarray platform and samples from set two were used for the RT-qPCR validation of miRNAs.
RNA isolation from blood and urine samples. Total RNA from the PAXgene™ blood samples was isolated using the PAXgene Blood miRNA kit (Qiagen, Hilden, Germany). The Norgen kit was used for the isolation of total RNA from urine samples including DNase treatment. RNA was collected in 300 µl elution buffer and concentrated using the Concentrator 5301 (Eppendorf, Hamburg, Germany). The concentrated RNA was dissolved in a final volume of 70 µl of RNase-free water. As we detected DNA despite the DNase treatment step in the Norgen isolation procedure, we executed an additional DNase treatment using the Ambion ® Turbo DNA-free™ kit (Applied Biosystems, Foster City, CA, USA). Quant-iT™ RiboGreen ® RNA reagent (Molecular Probes, Göttingen, Germany) was applied for urine RNA quantification on the LightCycler 1.5 (17) .
microRNA microarray experiments. Microarray experiments were carried out using TaqMan ® array human microRNA cards (Applied Biosystems) including 754 human miRNAs from the Sanger database v14 and 8 control miRNAs. The urine RNA samples were investigated using an additional pre-amplification step. Reverse transcription was performed with 3 µl blood RNA (~200 ng/µl) or urine RNA (~10 ng/µl). On the microarray cards, miRNAs were quantified until a Cq-threshold of 32. The expression level was calculated using the formula 2 -ΔCq and normalized to snRNA U6. In this report, the current nomenclature of miBase v 19 was used.
microRNA RT-qPCR. For each study group, 6 miRNAs were selected from the large number of differentially expressed miRNAs to validate them in blood and urine samples. The PCR reaction was carried out under the following conditions. Reverse transcription was performed using 6 ng blood and 1 ng urine RNA, respectively, and TaqMan ® microRNA reverse transcription kit (Applied Biosystems). In the case of blood samples, the PCR reaction included 1 µl miRNA-specific cDNA, 1X TaqMan ® Universal PCR Master Mix and gene-specific 1X TaqMan ® microRNA assay solution (Applied Biosystems). In the case of urine samples, a modification occurred, since 0.2X TaqMan ® MicroRNA assay solution was used. Afterwards a pre-amplification reaction only for the urine samples was performed with 1 µl cDNA, TaqMan ® Preamp Mix and gene-specific 0.05X TaqMan ® microRNA assay solution. Each PCR run included a non-template control with water instead of cDNA. An miRNA was detected with a Cq-value ≤35 and was normalized to the expression of small RNA U6 for blood miRNAs. The urine miRNAs were normalized to 1 ng urine RNA which was used for cDNA amplification. All PCR reactions with sample set one were carried out in triplicates.
All PCR reactions with the sample set two were carried out under the same conditions. All PCR reactions were carried out in duplicates. Standard curves of diluted miRNA-specific cDNA miR-26b-5p for blood and miR-29a-3p for urine as well as snRNA U6 from pooled normal bladder tissue was generated and used for calculation of expression values. The resulting expression values are provided as arbitrary units. The analytical reliability of PCR methods was characterized by the efficiency of amplification between 1.80 and 2.08 for snRNA U6 and miR-26b-5p, respectively. The precision of repeated measurements was tested with snRNA U6 (n=10) and miR-26b-5p (n=8) of 0.47 and 0.63% at threshold cycles (Cq-values) of 27.3±0.13 and 28.8±0.18, respectively. These details related to the blood RNA-isolates.
Sample set two (Table II) was used for validation. The blood miRNAs were normalized to snRNA U6 and the urine miRNAs to RNA concentration of the urine RNA isolate after concentration and DNase-treatment. Afterwards, the median expression for miRNA in each group was computed and tested for significance between the groups.
Statistical analysis. Statistical analyses were performed with the software GraphPad Prism for Windows, version 5 (GraphPad Software, San Diego, CA, USA). Outliers in the control groups were identified with the Grubbs' test. The two outliers in the blood control group were from the same healthy individuals and were excluded from further analysis. The samples from these individuals were collected in 2010 and no bladder cancer was diagnosed at the end of 2012. The outliers in the urine control group were caused by different healthy individuals so that these values were not excluded from further analysis. The Kruskal-Wallis and Mann-Whitney U tests were used for data comparison between groups. Medians were considered significantly different at P<0.05 (two tailed). Receiver operation characteristic (ROC) analysis (MedCalc, version 12 for Windows, Mariakerke, Belgium) was used to characterize the capacity of a single miRNA or a combination of miRNAs to discriminate between urine samples from controls and bladder cancer patients.
Results
Characteristics of the patient groups and samples. Blood and urine samples of set one were collected from 4 controls and 4 patients with superficial and invasive bladder cancer, respectively (Table I) . Sample set two included varying numbers of blood and urine samples of controls and patients with superficial tumours (Table II) . The analyzed blood and urine samples were not always collected from the same patient due to the very low RNA concentration in some urine samples. The median age between BC patients and the control group was significantly different (67 vs. 43 years, P<0.05) in blood and urine set two. To date, reports concerning age-dependent changes in miRNA expression in body fluids are not available. The snRNA U6 was undetectable in 13 of 55 urine RNA samples (23.6%), and was therefore not used for normalization. A similar observation was reported by Hanke et al (16) .
Identification of differentially expressed miRNAs with microarray experiments.
The characteristics of the RNA samples are summarized in Table III . After all preparation steps, the urine RNA concentrations were comparable (Kruskal-Wallis; P= 0.07) in all 3 groups (Fig. 1) . Several urine RNA isolates showed low RIN values <3. However, since the detection of miRNAs was not compromised in RNA preparations with a low RIN value (18) all preparations were used for further analysis. The microarray experiments identified >100 differentially expressed miRNAs in blood and >80 miRNAs in urine. In blood samples, only increased miRNAs were observed in comparison to the controls. The number of detected miRNAs in the tumour group was greater than that in the controls. In urine samples from invasive tumours, expression differences were observed for 60 miRNAs. A short list of differently expressed miRNAs in the samples are given in Tables IV and V. There was no similarity between miRNAs with the greatest expression differences between tumour and control in blood and in urine. Therefore, various miRNAs were selected for validation with RT-qPCR in blood and urine. miRNAs in the patient samples with an increased fold-change ≥2.5 or a decreased fold-change ≥10 were selected for further investigation. In addition, miR-139-5p was also selected for further validation as it showed a characteristic differential expression between tumour and normal tissues (6,7,10). Other miRNAs with expression alterations in tumour tissues such as miR-21 and miR-205 (19, 20) were not included in the validation set of miRNAs since they were not detected in the blood or urine samples.
Validation of differentially expressed miRNAs with RT-qPCR.
The quantification of blood miRNAs in sample set 2 showed an increased expression (≥2.0-fold) in invasive tumours Table IV . Short list of differentially expressed miRNAs in blood samples (microarray results). The 6 highlighted miRNAs in bold were selected for validation. miRNAs, microRNAs; hsa-miR, Homo sapiens miRNA. Table V . Short list of differentially expressed miRNAs in urine samples (microarray results). for miR-26b-5p, miR-144-5p and miR-374b-5p (Fig. 2) in comparison to the controls. The other 3 miRNAs (miR-139-5p, miR-574-3p, miR-625-3p) were only >1.5 times increased. The expression difference for these miRNAs observed in microarray experiments could not be reproduced in the RT-qPCR analysis. The expression of miRNAs miR-26b-5p (P<0.001), miR-144-5p (P=0.004) and miR-374b-5p (P=0.005) in blood of patients with invasive tumours was significantly increased in comparison to the control group. Only miR-374b-5p discriminated between control and patients with superficial tumours (P=0.038). Expression differences of the other 2 miRNAs (miR-26-5p, miR-144p) between patients with invasive and superficial tumours were not significant (Fig. 2) . When the blood samples from the cancer patients were compared as one group (invasive and superficial tumours together) with the control group, the expression differences were significant for all 3 miRNAs (miR-26b-5p, P=0.008; miR-144-5p, P=0.005 and miR-374b-5p, P=0.005).
Fold changes ---------------------------------------------------------------------------

Fold changes --------------------------------------------------------------------------
The validation of urine miRNAs in sample set two showed an increasing expression (≥2.0-fold) in invasive tumours for miR-520e, miR-618 and miR-1255b-5p. The expression of urine miRNAs miR-618 (P=0.042) and miR-1255b-5p (P=0.005) in invasive tumours was significantly increased in comparison to the control group. The expression of miR-520e showed a tendency for increased values (P=0.058) in the urine of the invasive tumour group compared with the controls. Significant expression differences of these miRNAs between invasive and superficial tumours were not observed (Fig. 3) . When the miRNAs of the urine samples from the entire tumour group were compared with those of the healthy controls, the expression differences were significant for miR-1255b-5p (P= 0.024).
Receiver operation characteristic (ROC) analysis.
ROC curve analysis demonstrated that each blood miRNA had a good specificity but low sensitivity for the identification of invasive tumours. All 3 urine miRNAs attained a sensitivity ≥70%, but the specificity was equally low for the identification of invasive tumours (Table VI) .
Discussion
miRNAs in blood and urine are of great interest from the diagnostic and prognostic point of view since they can be obtained by non-invasive or minimally invasive techniques. This is the first study concerning dysregulated miRNAs in whole blood samples from bladder cancer patients. From the 6 selected miRNAs that were found with increased expression in blood, 4 miRNAs (miR-26b-5p, miR-139-5p, miR-374b-5p, miR-574-3p) (6,7,10,11) were also identified as markers in bladder cancer tissue. We confirmed increased miR-26b-5p and miR-374b-5p values in blood samples that reflected the increased values already described in bladder cancer tissue samples (7, 11) . miR-26b-5p and miR-374-5p in blood showed both a specificity of 94% and sensitivities of 65 and 60%, respectively, in detecting invasive tumours. Levels of the other 2 miRNAs miR-139-5p and miR-574-3p were unchanged in blood whereas their expression was found reduced in tumour tissue (6, 7, 10) . Additionally, this study identified miR-144-5p in blood samples as a new marker of invasive bladder tumours. There are no reports available concerning miR-144-5p in bladder cancer patients. Expression alterations for the 3 miRNAs with increased expression found in the blood samples in this study were reported in connection with other carcinomas. Lung cancer showed alterations in miR-26b and miR-374 (21, 22) . Changes in miR-144 expression levels were observed in hepatocellular, lung and prostate cancer tissues (23) .
The investigation of miRNAs in whole blood samples includes miRNAs from blood cells, released tumour cells, exosomes as well as all circulating, cell-free miRNAs released from the tumour. Since the proportion of circulating miRNAs of the total miRNAs in blood samples is small, variations are mainly caused by the blood cells and may be the result of systemic reactions linked to the tumour disease. In conclusion, a tumour characteristic miRNA pattern results from a specific reaction of the organism (24, 25) .
The second part of the present study referred to the analysis of the RNA profile in urine. Reports on bladder cancer-specific miRNA signatures in urine samples are rare (12, 15, 16, (26) (27) (28) . Using the RT-qPCR-based microarray we investigated the abundance of 754 different human miRNA species. This is the most comprehensive examination of miRNA markers in urine after the report of Hanke et al (16) who tested 157 different human miRNAs. In several other studies (15, 26, 27) , miRNAs were selected as urinary markers based on the distinct expression differences found in tumour tissue. Other the authors investigated only urine sediment (12, 28) . However, most of the above analyzed miRNAs in those studies were not detectable in the present microarray analysis of urine specimens. miR-192 and miR-222 (28), although they were detected in all urine samples, were not selected for further investigations as the Cq-differences between samples from patients and controls were <2.
In urine of the BC patients, using the microarray approach, we identified the 2 miRNAs miR-29a-3p and miR-483-5p out of the 6 selected miRNAs that had previously been described as characteristic differentially expressed markers in bladder cancer tissue (7, 9) . However, these characteristics found in the initial sample set one could not be confirmed in sample set two. Still, the expression differences for miR-618 and miR-1255b-5p could be confirmed in the larger patient set two. For these 2 miRNAs, downregulated urinary excretion data has been described in hepatocellular and renal carcinoma (29, 30) . Both miRNAs may be linked with carcinomas but the origin of their occurrence in urine is unclear. The expression of miR-520e showed a tendency for increased values in the urine of the invasive tumour group compared with the controls. The findings of Zhang et al (31) suggest that miR-520e may be a tumour-suppressor miRNA in hepatocellular carcinomas since NF-κB-inducing kinase is one of the direct target genes of miR-520e. Further studies with a large sample size will confirm this tendency.
Commonly, small RNAs are used as endogenous controls to normalize the expression data of miRNAs in tissues. Our results showed that these endogenous controls are not suitable for normalization of urine data as snRNA U6 was not expressed equally in all samples. A systematic evaluation of normalization approaches including the use of potential reference genes for the analysis of urine miRNA has been lacking to date. For this reason, we normalized the miRNA excretion using the same quantity of total RNA for all measurements. This approach to normalization by using total RNA was suggested by Bustin (32) when reliable reference genes are not available. However, this approach requires a reliable quantification of RNA, which we achieved, despite the low RNA concentrations, using the fluorimetric RNA assay with RiboGreen ® (17). In conclusion, this pilot study discovered three dysregulated miRNAs in whole blood and 2 others in urine for the identification of bladder cancer patients. miR-26b-5p is significantly increased in the blood of invasive bladder cancer patients and increased miR-1255b-5p in urine samples is also characteristic. The receiver operating characteristic curve analyses indicated that blood miR-26b-5p alone (AUC=0.824) and urine miR-1255b-5p alone (AUC= 0.764) provide significant accuracy for invasive bladder cancer diagnosis. This study serves as a basis for further studies to specify useful blood and urine miRNA signatures and their application for initial bladder cancer detection and surveillance.
